05:45 PM EDT, 09/16/2024 (MT Newswires) -- Clearmind Medicine ( CMND ) said late Monday that it applied for an international patent application for its combination therapy of N-Acylethanolamines and Ibogaine, which is considered a potentially effective anti-addiction agent.

The application follows developments in collaboration with SciSparc ( SPRC ) . The companies are researching new combination therapies that integrate psychedelic compounds with the N-Acylethanolamines family, Clearmind said.

The company's shares were up more than 2% in after-hours activity, while SciSparc ( SPRC ) jumped 16%.

Price: 1.3600, Change: +0.03, Percent Change: +2.26